31
Marc J Ostro, Andrew S Janoff, Sharma R Minchey: Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations. The Liposome Company, Kenneth B Rubin, Rosanne Goodman, September 22, 1998: US05811118 (5 worldwide citation)

This invention provides a method of administering an arachidonic acid metabolite, such as prostaglandin E1, to an animal. The metabolite is given to the animal, typically a human, in association with a unilamellar liposome comprising a lipid and a release-inhibiting aqueous buffer. This method can b ...


32
Robert Kruse, Sudhish Chandra, Fred Feldman: Treatment of immobilized matrices for preparation of pharmaceutical and biological products with anti-microbial agents to remove pyrogen-producing organisms and pyrogens. Armour Pharmaceutical Company, Martin F Savitzky, Rosanne Goodman, Raymond S Parker, April 13, 1993: US05202246 (5 worldwide citation)

Disclosed are methods of inactivating pyrogen producing organisms and pyrogenic substances in immobilized solid matrices which are used in the production and/or purification of biomedical and pharmaceutical products and materials by contacting the solid matrices with pyrogen inactivating solutions.


33
Thomas V Magee, Anthony Marfat, Robert J Chambers: Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes. Pfizer, Charles W Ashbrook, Paul M Misiak, Rosanne Goodman, July 31, 2007: US07250518 (4 worldwide citation)

Compounds of the formula: useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils.


34
Eric Mayhew, Andrew S Janoff, Imran Ahmad, Suresh K Bhatia: Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes. The Liposome Company, Rosanne Goodman, December 28, 1999: US06007839 (4 worldwide citation)

Described herein are methods of preparing liposome-containing pharmaceutical compositions, the liposomes containing headgroup-derivatized lipids and etherlipids having the formula: ##STR1## Such compositions are useful in the treatment of a variety of conditions, including various cancers and inflam ...


35
Timothy E Benson, Donald Bryan Prince: Crystallization and structure determination of Staphylococcus aureus NAD synthetase. Pharmacia & Upjohn Company, Rosanne Goodman, January 17, 2006: US06988041 (4 worldwide citation)

An unliganded form of Staphylococcus aureus NAD synthetase (S. aureus NadE) has been crystallized, and the three-dimensional x-ray crystal structure has been solved to 2.3 Å resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and des ...


36
Andrew S Janoff, Joyce Rauch, Theodore F Taraschi: Lipid-dependent diagnostic assays. The Liposome Company, Rosanne Goodman, July 17, 2001: US06261792 (4 worldwide citation)

For use in a lipid-dependent diagnostic assay, a stable aqueous suspension of a phospholipid which normally has a hexagonal (H


37
Claudio Falcone, Reinhard Fleer, Michele Saliola: Yeast promoter and its use. Rhone Poulenc Rorer, Julie K Smith, Rosanne Goodman, Martin F Savitzky, May 6, 1997: US05627046 (4 worldwide citation)

DNA sequences comprising all or part of the ADH4 gene promoter of K. lactis or a derivative of the latter, and having transcriptional promoter activity. The invention also concerns the use of said sequences for the expression of recombined genes.


38
Gregory R Mundy, Gloria E Gutierrez, Ian R Garrett, Massimo Sabatini, Elzbieta Izbicka, Wilson Burgess, Gregg R Crumley, Clarence C Morse, Timothy R Arnett: Process of purifying antler-derived bone growth factors. Rhone Poulenc Rorer Pharmaceuticals, OsteoSA, Rosanne Goodman, Martin F Savitzky, April 18, 1995: US05408041 (4 worldwide citation)

The present invention relates to the development of bone growth factors as therapeutics for the prevention and treatment of pathological conditions involving bone tissue. The present invention provides biologically active proteinaceous factors comprising polypeptides containing the amino acid sequen ...


39
Michael J Munchhof, Laura C Blumberg: Imidazole compounds as transforming growth factor (TGF) inhibitors. Pfizer, Pfizer Products, Christine Lee, Rosanne Goodman, Charles W Ashbrook, December 26, 2006: US07153872 (3 worldwide citation)

Novel imidazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-β• signaling p ...


40
Jack Newman, David L Farb: Purification of vonwillebrand factor by affinity chromatography. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, Rosanne Goodman, Martin F Savitzky, April 9, 1996: US05506341 (3 worldwide citation)

A method of improving the therapeutic activity of von Willebrand Factor obtained from materials comprising said Factor comprising incubating said Factor at a temperature of about 20.degree. C. to about 55.degree. C. for about 1 to about 30 hours.